• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Bonnie W Ramsey, Margaret Sullivan Pepe, +9 authors Andrew L Smith
  • Medicine
  • The New England journal of medicine
  • 1999 (First Publication: 7 January 1999)
  • BACKGROUND AND METHODS We conducted two multicenter, double-blind, placebo-controlled trials of intermittent administration of inhaled tobramycin in patients with cystic fibrosis and PseudomonasContinue Reading
  • Drucy Borowitz, Richard B. Parad, +9 authors Frank Accurso
  • Medicine
  • The Journal of pediatrics
  • 2009 (First Publication: 1 December 2009)
  • Through early detection, newborn screening (NBS)(1) for cystic fibrosis (CF) offers the opportunity for early intervention and improved outcomes. NBS programs screen for hypertrypsinogenemia, andContinue Reading
  • Vin Tangpricha, Andrea B Kelly, +5 authors Drucy Borowitz
  • Medicine
  • The Journal of clinical endocrinology and…
  • 2012 (First Publication: 1 April 2012)
  • OBJECTIVE The objective was to develop evidence-based clinical care guidelines for the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosisContinue Reading
  • Steven M. Rowe, S Heltshe, +9 authors Bonnie W. Ramsey
  • Medicine
  • American journal of respiratory and critical care…
  • 2014 (First Publication: 15 July 2014)
  • RATIONALE Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation. OBJECTIVES ToContinue Reading
  • Edward F. McKone, Drucy Borowitz, +10 authors Jane C Davies
  • Medicine
  • The Lancet. Respiratory medicine
  • 2014 (First Publication: 1 November 2014)
  • BACKGROUND Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, is approved for the treatment of patients with cystic fibrosis aged 6 years or older withContinue Reading